Navigation Links
Medco CEO Reiterates Guidance, Positive Outlook for 2008
Date:1/8/2008

FRANKLIN LAKES, N.J., Jan. 8 /PRNewswire-FirstCall/ -- Medco Health Solutions, Inc. (NYSE: MHS) Chairman and CEO, David B. Snow Jr. today reiterated the company's positive outlook for 2008 at the 26th Annual JPMorgan Healthcare Conference in San Francisco.

The company reiterated its guidance for 2008 GAAP diluted earnings per share of $3.89-$4.01. Excluding the amortization of intangible assets that existed when Medco became a publicly traded company, Medco continues to expect 2008 diluted earnings per share in the range of $4.29-$4.41 per share (please see Medco's filings with the Securities and Exchange Commission for a Reconciliation of earnings per share guidance). This guidance does not include possible unscheduled releases of generics, such as Protonix or Effexor.

About Medco

Medco Health Solutions, Inc., (NYSE: MHS) is the nation's leading pharmacy benefit manager based on its 2006 total net revenues of more than $42 billion. Medco's prescription drug benefit programs, covering one in five Americans, are designed to drive down the cost of pharmacy healthcare for private and public employers, health plans, labor unions and government agencies of all sizes, and for individuals served by the Medicare Part D Prescription Drug Program. Medco, the world's most advanced pharmacy(TM), has created Medco Therapeutic Resource Centers(TM) that are staffed with hundreds of specialist pharmacists who are trained and certified in specific chronic and complex conditions and have expertise in the associated medications. With the 2007 acquisition of Liberty Medical, Medco is the nation's largest diabetes pharmacy care practice based on covered lives. Medco is the largest specialty pharmacy based on net revenues with the 2005 acquisition of Accredo Health Group, Inc. Medco is also the highest-ranked independent pharmacy benefit manager on the 2007 Fortune 500 list. On the Net: http://www.medco.com.

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. We undertake no obligation to publicly update any forward- looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the risks and uncertainties that affect our business, particularly those mentioned in the Risk Factors section of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission.


'/>"/>
SOURCE Medco Health Solutions, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MedcomSoft Receives 2007s "Best in KLAS" EMR Ranking (1-5 Physicians)
2. MedcomSoft appoints former U.S. presidential health advisor, James Haveman, to health Care advisory board
3. URAC Names Medco as a Finalist in First-ever Best Practices in Consumer Empowerment and Protection Awards
4. Medco Announces Two-For-One Stock Split
5. Medco CEO to Present at the Merrill Lynch & Co., Inc. 2007 Health Services Investor Conference
6. Medco Elects Myrtle Potter, William Roper to Board of Directors
7. Medco to Build Worlds Largest, Most Advanced Automated Pharmacy in Central Indiana
8. Medco, LabCorp Strike Strategic Agreement for Research on Personalized Medicine and Pharmacogenomics
9. Six Olympic Legends Battling Chronic Diseases Lead Revolution in Advancing Pharmacy Care as Medco Launches the Tour of Champions
10. Medco Announces Date for Third-Quarter 2007 Financial Results
11. Medco Unveils Three New Medicare Prescription Drug Plan Options for 2008 to Provide Seniors More Choice, Better Value and Specialist Pharmacists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... ... May 30, 2016 , ... Shaolin ... warrior 8-day-8 and 8-night special intensive summer training camp starts on June 17th ... camp offers families and children a fun and unique experience with an opportunity ...
(Date:5/29/2016)... ... May 29, 2016 , ... "With 30 unique self-animating ... user control the style of their project," said Christina Austin - CEO of Pixel ... web-themed intros created exclusively for use in Final Cut Pro X. Pixel Film Studios’ ...
(Date:5/28/2016)... ... May 28, 2016 , ... After a year and a half of planning the ... extraordinary event. The Multiple Pathways of Recovery Conference was held May 2 -4, 2016 ... and the United Kingdom came together to explore the many pathways individuals use to get ...
(Date:5/27/2016)... ... 27, 2016 , ... Two director-level employees of Horizon Blue Cross Blue Shield ... (TWIN) 2016 honorees. The award recognizes businesswomen who excel in their fields and ... of the MLTSS (Managed Long-Term Services and Supports) Program at Horizon NJ Health and ...
(Date:5/27/2016)... ... May 27, 2016 , ... This campaign aims to provide ... we as a society can control and change. , As nearly 795,000 Americans suffering ... seconds within the United States. Plus, with an estimated 129,000 of these people dying ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... May 26, 2016 TARE ... Both Cost Savings and Overall Decreased Use ... BTG), an international specialist healthcare company, has today ... 21st Annual Meeting of ISPOR (International Society for ... hepatocellular carcinoma (HCC) using yttrium-90 glass microspheres is ...
(Date:5/25/2016)... May 25,2016 FDA 510(k) ... Cellvizio platform for urological and surgical applications ... inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy ... in the US with the 12 th ... Administration (FDA). This new FDA clearance covers Confocal ...
(Date:5/25/2016)... HILDEN , Germany and ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt ... into a licensing and co-development agreement with Therawis Diagnostics GmbH ... project will be to develop and market PITX2 as a ... and other high-risk breast cancer patients. "We are ...
Breaking Medicine Technology: